Table 4.
Comparison of Clinical Courses and Management Among the Subgroups
| Total (N = 137) | E Group (n = 14) | P Group (n = 96) | N Group (n = 27) | P Value | |
|---|---|---|---|---|---|
| Use of inotropics, n (%) | 51 (37) | 2 (14) | 42 (44) | 7 (26) | 0.041a |
| Use of IABP, n (%) | 16 (12) | 0 (0) | 14 (15) | 2 (7) | 0.211 |
| Use of ACEI or ARB, n (%) | 79 (58) | 12 (86) | 44 (46) | 23 (85) | 0.001a |
| Use of β‐blocker, n (%) | 26 (19) | 4 (29) | 15 (16) | 7 (26) | 0.303 |
| Use of diuretic, n (%) | 61 (45) | 2 (14) | 45 (47) | 14 (52) | 0.047a |
| Temporal pacemaker, n (%) | 10 (7) | 0 (0) | 8 (8) | 2 (7) | 0.534 |
| Cardioversion, n (%) | 8 (6) | 0 (0) | 7 (7) | 1 (6) | 0.163 |
| ICU hospitalization, n (%) | 92 (67) | 8 (57) | 59 (62) | 25 (93) | 0.007a |
| ICU hospitalization, db | 2.0 (0–5.0) | 1.0 (0–2.0) | 3.0 (0–5) | 2.0 (2–4) | 0.014a |
| Hospitalization, db | 14.0 (7.0–28.0) | 3.0 (3.0–9.0) | 17.0 (8.0–32.0) | 8.0 (5.0–14.0) | 0.001a |
| In‐hospital cardiac mortality, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NS |
| Cardiac mortality during follow‐up, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NS |
| Mortality during follow‐up, n (%) | 12 (9) | 1 (7) | 10 (10) | 1 (4) | 0.538 |
| Recurrence, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | NS |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; IABP, intra‐aortic balloon pump; ICU, intensive care unit; NS, not significant.
a
Significant finding.
b
Presented as median (interquartile range).